IMM 5.36% 29.5¢ immutep limited

Immutep will conduct a new Phase IIb clinical trial in 1st...

  1. 25,326 Posts.
    lightbulb Created with Sketch. 1375
    Immutep will conduct a new Phase IIb clinical trial in 1st line
    HNSCC patients, as initially described in the ASX announcement dated 28 September 2020.

    Immutep maintains control of trial, very important in my mind for any commercial discussions which
    may take place in the future.......Merck increasing supply agreement, presumably with more interest...
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
29.5¢
Change
0.015(5.36%)
Mkt cap ! $428.5M
Open High Low Value Volume
28.5¢ 30.5¢ 28.0¢ $833.4K 2.824M

Buyers (Bids)

No. Vol. Price($)
8 388130 29.5¢
 

Sellers (Offers)

Price($) Vol. No.
30.0¢ 39940 3
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.